^
    almost3years
    Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study. (PubMed, Front Oncol)
    A total of 19 patients were confirmed to have received EGFR tyrosine kinase inhibitors (TKIs), but the response to EGFR-TKIs differed among patients with different EGFR mutations. Chinese patients with lung cancer harbored unique and dispersive EGFR germline mutations and showed unique clinical and genetic characteristics, with varied response patterns to EGFR-TKI treatment.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR K757R • EGFR R776H • EGFR V774M
    over3years
    [VIRTUAL] EGFR Germline Mutations in Chinese Lung Cancer Patients: A Single Institutional, Retrospective Study (IASLC-WCLC 2021)
    One patient harboring germline T790M mutation and somatic L861Q and G719A mutations received icotinib and the DOT was 15 months...One patient with germline P848L mutation did not respond to either ecotinib or afatinib. Another patient with germline R831H mutation received gefitinib treatment and the progression-free survival was 14 months. Conclusion This study identified more EGFR germline variants other than the previously reported T790M mutation. Patients with EGFR germline variants may benefit from TKIs treatment.
    Retrospective data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719A • EGFR K757R
    |
    Gilotrif (afatinib) • gefitinib • Conmana (icotinib)